Healthcare company CVS Health has launched its Clinical Trial Services business to improve access to clinical trials, as well as enhance participant retention and research efficacy.
The new unit partnered with biopharmaceutical and clinical trial stakeholders to develop new methods for research and obtaining real-world data.
CVS Health Clinical Trial Services will use analytics, its presence in the US and domestic network to spread awareness on clinical trial opportunities.
The aim is also to design decentralised approaches to deliver Phase III/IV trials and real-world evidence studies at CVS sites, at home or virtually.
CVS added that the focus will be on studies for treatments and medical devices in real-world settings.
The company worked with the pharmaceutical industry to enable Covid-19 vaccines and therapies trials.
It leveraged a digital model and specific screening protocols to engage approximately 300,000 individuals meeting Covid-19 vaccine trials’ inclusion criteria and directed them to nearby studies.
CVS Health executive vice-president and chief medical officer Troyen Brennan said: “Traditionally low patient enrolment, diversity and engagement coupled with inconvenient trial sites, challenging study participation requirements, including the length of participation, show the need to improve the current model particularly in response to the Covid-19 pandemic.
“Combining clinical trial expertise from across the CVS Health enterprise with our growing connection to the communities we serve, will help create a new clinical trial experience that works better for participants, health care providers, clinical research organisations and study sponsors.”
The new clinical trials services unit will build on the company’s healthcare services and clinical research capabilities, including nearly 200 at-home trials, real-world studies and support for publishing peer-reviewed articles.